Synonyms: GENZ-112638
eliglustat is an approved drug (FDA (2014), EMA (2015))
Compound class:
Synthetic organic
Comment: The marketed formulation contains eliglustat tartrate (PubChem CID 52918379).
|
|
References |
1. Larsen SD, Wilson MW, Abe A, Shu L, George CH, Kirchhoff P, Showalter HD, Xiang J, Keep RF, Shayman JA. (2012)
Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res, 53 (2): 282-91. [PMID:22058426] |
2. Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Kamath RS, Rosenthal DI et al.. (2010)
Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood, 116 (20): 4095-8. [PMID:20713962] |
3. Lukina E, Watman N, Dragosky M, Pastores GM, Arreguin EA, Rosenbaum H, Zimran A, Angell J, Ross L, Puga AC et al.. (2014)
Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis, 53 (4): 274-6. [PMID:24835462] |